English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic hepatitis C (CHC) is one of the main leading causes of mortality associated with liver disease worldwide. Different predominant modes of transmission in the local area play an important role for the disease burden. Several cofactors are identified to accelerate the disease progression. Besides, several comorbidities are common in patients with CHC and also have poor response to the traditional combination of pegylated interferon and ribavirin (PegIFN/RBV) treatment. The treatment of CHC has been evolved rapidly, the traditional treatment of choice PegIFN/RBV lasts more than a decade but the cure rate remains unsatisfied and shows heterogeneous response in various patient groups. In addition, considerable patients are intolerable to adverse reactions of PegIFN/RBV. The newly developed IFN-free regimens, oral direct antiviral agents (DAAs), lead to high SVR, short treatment duration and enhance tolerability. Also, the treatment of DAAs have been grown since 2011 persistently. The new generations of DAAs improved cure rate, tolerability and lead to more convenient administration. Some special populations, who are difficultly treated with PegIFN/RBV therapy, can also benefit from the new DAAs. There are some concerns still warranted in DAAs therapy, including drug-drug interactions between DAAs and co-medication for the comorbidity, severe renal impairment and decompensated liver disease, co-infection with HIV/HCV and HBV/HCV. Generally, cure of CHC become more possible but there are some aspects provided for clinical heath caregivers for better DAAs management.

New Perspectives of HCV Infection: Focus on New Treatment Agents and Comorbidity Status, a Short Review